Last reviewed · How we verify

Dexmedetomidine and Fentanyl

University of Jordan · Phase 3 active Small molecule

Dexmedetomidine and fentanyl work synergistically as a sedative-analgesic combination, with dexmedetomidine acting as an alpha-2 adrenergic agonist and fentanyl as an opioid mu-receptor agonist.

Dexmedetomidine and fentanyl work synergistically as a sedative-analgesic combination, with dexmedetomidine acting as an alpha-2 adrenergic agonist and fentanyl as an opioid mu-receptor agonist. Used for Sedation and analgesia in perioperative and critical care settings.

At a glance

Generic nameDexmedetomidine and Fentanyl
Also known asPrecedex
SponsorUniversity of Jordan
Drug classSedative-analgesic combination (alpha-2 agonist + opioid)
TargetAlpha-2 adrenergic receptor (dexmedetomidine); mu-opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia and Perioperative Medicine
PhasePhase 3

Mechanism of action

Dexmedetomidine selectively binds alpha-2 adrenergic receptors in the central nervous system to produce sedation, analgesia, and anxiolysis while maintaining airway reflexes. Fentanyl is a potent synthetic opioid that binds mu-opioid receptors to enhance analgesia and sedation. The combination provides complementary effects for perioperative sedation and analgesia with potentially reduced opioid requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: